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Abstract 
Objectives/Background. Ecstasy/polydrug users have exhibited deficits in laboratory 
tests of executive functioning. We sought to extend these findings by investigating the extent 
to which ecstasy/polydrug users manifest executive deficits in everyday life. Methods. Forty-
two current ecstasy/polydrug users, 18 previous (abstinent for at least 6 months) 
ecstasy/polydrug users, and 50 non-users of ecstasy (including both non-users of any illicit 
drug and some cannabis-only users) completed the self-report Behavior Rating Inventory of 
Executive Function-Adult Version (BRIEF-A) measure. Results. Current ecstasy/polydrug 
users performed significantly worse than previous users and non-users on subscales 
measuring inhibition, self-monitoring, initiating action, working memory, planning, 
monitoring ongoing task performance, and organizational ability. Previous ecstasy/polydrug 
users did not differ significantly from nonusers. In regression analyses, although the current 
frequency of ecstasy use accounted for statistically significant unique variance on 3 of the 9 
BRIEF-A subscales, daily cigarette consumption was the main predictor in the 6 other 
subscales. Conclusions. Current ecstasy/polydrug users report more executive dysfunction 
than do previous users and nonusers. This finding appears to relate to some aspect of ongoing 
ecstasy use and seems largely unrelated to the use of other illicit drugs. An unexpected 
finding was the association of current nicotine consumption with executive dysfunction. 
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Executive functions have been described as “a collection of correlated but separable 
control processes that regulate lower level cognitive processes to shape complex 
performance” (p 201).1 Executive functions are known to rely heavily on prefrontal cortical 
structures, most notably the dorsolateral prefrontal cortex.
2
 These functions underpin 
performance in a range of domains, thereby supporting the most cognitively demanding 
aspects of human behavior.
3
 
A relatively new line of investigation evaluates the integrity of executive functioning 
in users of recreational drugs, specifically ecstasy, cannabis and cocaine  The psychoactive 
ingredient in ecstasy 3,4-methylenedioxy-N-methylamphetamine, (MDMA) is known to have 
neurotoxic effects on serotonergic axon terminals in both animals and humans.
4
 In view of 
the important role that serotonin plays in regulating prefrontal neural processes,
5
 the 
possibility that executive processes are impaired in former and current ecstasy users deserves 
serious consideration. Most such assessment in the area of recreational drug use has been 
restricted to laboratory-based measures; a number of laboratory-based studies have 
demonstrated deficits among currently abstinent ecstasy users (see Murphy, Wareing, Fisk, et 
al
6
 for a review). 
To supplement the insights gained from laboratory-based neuropsychological tests, 
investigators have developed self-report measures designed to evaluate an individual’s day-
to-day executive functioning in the real world. By offering environmental, contextual 
indicators of executive processes, self-report measures provide a useful complement to 
“snapshot” laboratory-based measures obtained during a single assessment. 
One of the best established self-report measures is the Behavior Rating Inventory of 
Executive Function (BRIEF)
7
, which includes questions about everyday activities in familiar 
contexts that respondents can readily identify with. The BRIEF captures the behavioral 
manifestations of executive dysfunction in the interrelated behavioral domains commonly 
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discussed in the literature.
8
 Each of the BRIEF’s 9 subscales assesses a separate aspect of 
executive functioning. The 9 subscales are termed as Inhibit, Shift, Emotional Control, Self-
Monitor, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of 
Materials. The BRIEF has been used in a wide range of research, eg,  attention deficit/ 
hyperactivity disorder,
9-13
  bipolar disorder,
14
 autism spectrum disorders,
10,15-16
 childhood 
epilepsy,
17
 frontal lobe lesions,
18
 and traumatic brain injury.
10,19
  
Although laboratory tests are important in identifying impairments in executive 
processes, it is not always easy to draw inferences from the results about which specific 
aspects of everyday behavior may be adversely affected. The BRIEF’s multidimensional 
nature and its ability to tap manifestations of executive functioning in everyday settings give 
us a more comprehensive view of executive deficits among young adults who use ecstasy and 
other illicit drugs recreationally. 
Given that laboratory measures of executive function have shown ecstasy-related 
deficits, we predicted that ecstasy users would show impairment on at least some of the 
BRIEF subscales. Past research (eg, Wareing and co-workers
20,21
) has suggested that 
executive function deficits persist  in former ecstasy users who have been abstinent for a long 
time. We predicted, therefore, that both current and previous ecstasy users would be equally 
susceptible to executive deficits. 
 
METHODS 
 
Participants 
We evaluated 110 students who were attending the University of Central Lancashire 
or Liverpool John Moores University. We recruited using the “snowball technique,” ie, word-
of-mouth referral.
22
 Of the total participants, 42 (21 men, 21 women) were current 
Fisk:  Executive Dysfunction in Illicit Drug Users   5 
 
ecstasy/polydrug users, 18 (4 men, 14 women) were previous ecstasy/polydrug users who had 
been abstinent for at least 6 months, and 50 (12 men, 38 women) were non-users of ecstasy; 
this last group included both non-users of any illicit drugs and some cannabis-only users. We 
defined polydrug use as the use of two or more psychoactive drugs. All of our 
ecstasy/polydrug users were users of ecstasy who also used other psychoactive drugs such as 
cannabis and cocaine. All of the participants consumed legal drugs such as alcohol, and a 
substantial minority smoked cigarettes (Table 1).  
<<Insert Table 1 About Here>> 
Procedures 
We informed the participants about the general purpose of the study and their right to 
withdraw at any time. After they gave their verbal consent to participate, they took the tests in 
a quiet laboratory. In order to protect the student’s anonymity, written consent was not 
obtained. First we obtained data on their age, sex, years of education, and current use of 
alcohol and cigarettes. Alcohol consumption was measured in units, where, for example, a 
glass of wine, a single measure of spirits or a half a pint of beer is equivalent to one unit. 
Then we assessed their history of illicit drug consumption with a background drug-use 
questionnaire that has been used extensively in previous research (eg, Montgomery, Fisk, 
Newcombe, et al
23
). The responses enabled us to estimate total lifetime use for each drug 
(ecstasy, cannabis, cocaine, amphetamines, etc), frequency of use, and period of abstinence. 
We used Raven's Progressive Matrices
24
 to measure the participants’ fluid intelligence.   
Then we gave this sequence of tests (each is described below): the EMQ, PRMQ, CFQ, and 
BRIEF-A. 
The participants also completed a range of other laboratory-based measures, the 
results of which are beyond the scope of this study and are reported elsewhere.
32,33
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At the end of the experiment, the participants were fully debriefed, paid £20 UK in 
Tesco store vouchers, and given drug education leaflets. We handed them the CFQ for Others 
and asked them to give it to their relative, partner, or housemate to complete and return in a 
pre-paid addressed envelope. 44 completed questionnaires were returned.  
The study was approved by the ethics committees of Liverpool John Moores 
University and the University of Central Lancashire. 
 
Self-Report Measures 
Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A). Many 
studies have shown the reliability and validity of the BRIEF in assessing executive 
functions.
8,10, 13, 25-26
 The BRIEF-A
7
 is a 75-item measure of 9 aspects of executive function: 
 Inhibit : ability to resist or control impulses (8 items), eg, “I tap my fingers or bounce my 
legs.” 
 Shift:  ability to shift attention, change strategies, and act flexibly (6 items), eg, “I have 
trouble changing from one activity to another.” 
 Emotional Control: ability to control one’s emotions (10 items), eg, “I have angry 
outbursts.” 
 Ability to Self-Monitor: sensitivity, ability to infer the feelings and emotions of others, and 
behaving in a thoughtful manner (6 items), eg, “I don't notice when I cause others to feel 
bad or get mad until is too late.” 
 Ability to Initiate: having the impetus to begin tasks, generate ideas, and develop strategies 
(8 items), eg, “I need to be reminded to begin a task even when I am willing.” 
 Working Memory: temporary storage and maintenance of information while working on 
ongoing tasks (8 items), eg, “I have trouble concentrating on tasks (such as chores, reading, 
or work).” 
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 Ability to Plan/Organize: setting goals and developing tactics to achieve them, anticipating 
future events, and preparing strategies to deal with them (10 items), eg, “I get overwhelmed 
by large tasks.” 
  Task Monitor:  ability to appraise task requirements and avoid making careless mistakes (6 
items), eg, “I make careless errors when completing tasks.” 
 Organization of Materials: being organized and tidy (8 items), eg, “I am disorganized.”  
For each item, participants respond on a 3-point scale: Never (1 point), Sometimes (2 
points), Often (3 points). For each of the 9 subscales, the scores for the relevant questions are 
combined to make the total score. Higher scores on each subscale indicate more executive 
dysfunction. 
The 9 BRIEF-A subscales map onto 2 higher-level indices: the Behavioral Regulation 
Index and the Metacognition Index -. The Behavioral Regulation Index, a measure of a 
person’s ability to maintain appropriate regulatory control of behavior and emotional 
responses, combines the first 4 BRIEF-A subscales: Inhibit, Shift, Emotional Control, and 
Self-Monitor. The Metacognition Index, a measure of a person’s ability to solve different 
kinds of problems systematically through effective planning and organization, combines the 5 
other BRIEF-A subscales: Initiate, Working Memory, Plan/Organize, Task Monitor, and 
Organization of Materials. The Behavioral Regulation Index and Metacognition Index, in 
turn, map onto a single total executive function score called the Global Executive Composite. 
As with the individual subscales, higher Behavioral Regulation Index, Metacognition Index, 
and Global Executive Composite scores indicate more executive dysfunction. 
An additional 3 scales—infrequency, negativity, and inconsistency—measure the 
validity and reliability of the participant’s responses.   Infrequency is the extent to which a 
respondent endorses items that the vast majority of people reject (5 items), eg, “I forget my 
name.” Scores on certain other items are combined to form indicators of ‘negativity’ and 
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‘inconsistency’. Negativity is the tendency to perceive oneself in an unduly negative manner, 
relative to the norm. Inconsistency is the tendency to give different answers to similar 
questions. High scores on any of these 3 scales potentially compromise the BRIEF-A’s 
validity.  
 
 
Everyday Memory Questionnaire (EMQ). The EMQ
 27,28
 is a self-report measure of 
memory lapses in everyday activities. The measure consists of 27 statements like “forgetting 
where you put something” and “finding a television story difficult to follow.” Participants 
respond on a 9-point scale ranging from “not at all in the last 6 months” to “more than once a 
day.” The total score is the sum of responses on all items. 
 
Cognitive Failures Questionnaire (CFQ). The CFQ
29
 is a 25-item measure of everyday 
attentional deficits, with questions like “Do you fail to notice signposts on the road?” and 
“Do you start doing one thing at home and get distracted into doing something else?” 
Participants respond on a 5-point scale with zero being “never” and 4 being “very often.” The 
maximum score is 100. 
 
Cognitive Failures Questionnaire (CFQ) for Others. To assess the accuracy of our 
participants’ responses, we asked them to give the CFQ for Others29 to a “significant other,” 
ie, someone who had a reasonable knowledge of the participant’s real-world behavior. In the 
original study of the CFQ for Others, Broadbent et al
 
surveyed participants’ family members 
or partners, but because we were studying a student population, we followed Smith-Spark et 
al
30
 and considered a “housemate” to be a significant other. The respondent was asked to 
complete the questionnaire and return it to us in a pre-paid addressed envelope. 
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Each of the 8 questions started with, “During the last six months has your 
relative/partner/housemate seemed to be...” The question then asked about a different type of 
behavior, eg, “disorganized, that is, getting into a muddle when doing something because of 
lack of planning or concentration?” The respondent selected one of the following responses: 
Very Often (5 points), Quite Often (4 points), Occasionally (3 points), Very Rarely (2 points), Never 
(1 point). For half of the questions, these response alternatives were listed underneath from left to 
right, for the other half they were listed underneath from right to left. The total score is the sum of 
the individual item scores (maximum 40) with a high score indicative of more cognitive 
failures.  
 
Prospective and Retrospective Memory Questionnaire (PRMQ).
 
The PRMQ
31
 is a 
measure of memory slips.  Half of its16 items ask about prospective memory failures, and 
half about retrospective failures, eg, “Do you fail to recall things that have happened to you in 
the last few days?” Participants say how often these things have happened to them, using a 5-
point scale: five being “very often”, four being “quite often”, three being “sometimes”, two 
being “rarely”, or one being “never”. Scores can range from 8 to 40. For our study, we used 
only the retrospective memory scores. 
 
 
 
Statistical Design 
As dependent variables, we used the 9 subscales of the BRIEF-A. The independent 
variable was drug use with three levels (current ecstasy user, previous ecstasy user, and non-
user of ecstasy). Covariates were alcohol and cigarette smoking. 
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We conducted regression analyses with the BRIEF-A subscales as dependent 
variables and, as independent variables, the current frequency of ecstasy, cannabis, and 
cocaine use and current cigarette and alcohol use. 
We ran correlations between the BRIEF-A measures (the subscales and the higher-
order executive function composites) and the periods of abstinence for ecstasy, cannabis, and 
cocaine.  
We ran partial correlations between the BRIEF-A scores and the measures of 
everyday memory, self-reported retrospective memory, and cognitive failures. The self-
reported memory measures and cognitive failures served as controls in successive analyses. 
 
 
RESULTS 
Using the criteria suggested by Tabacknick and Fidell,
34
 we found no univariate 
outliers. One multivariate outlier was identified and excluded from further analysis. The 
BRIEF-A validity subscales for infrequency, negativity, and inconsistency did not reveal any 
response patterns that might justify excluding a participant. Thus, we were able to analyze the 
data on all 110 participants. We also found that the distribution of the BRIEF-A subscale 
scores did not deviate significantly from normal. In relation to skewness and kurtosis, the z-
scores associated with the statistics were all less than 3, P > 0.001 in all cases, which is 
consistent with normality for samples of this size.
34
  
 On their background demographics and use of legal drugs, the 3 study groups 
differed significantly only in their alcohol use (Table 1). Tukey’s post-hoc test revealed that 
only 1 of the pairwise comparisons was statistically significant: current ecstasy/polydrug 
users consumed significantly more units of alcohol per week than non-users of ecstasy, P = 
0.007. During the previous three months, 7 of the current ecstasy users, reported occasionally 
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using amphetamine, 2 DOB (2,5-Dimethoxy-4-bromoamphetamine,) 13 ketamine, and 4 
LSD. Similarly, 3 of the previous ecstasy users reported occasionally using ketamine and 1, 
LSD.  In addition to ecstasy, the most frequently used illicit drugs were cannabis and cocaine. 
Table 2 shows the 3 groups’ use of these drugs. Among the non-users of ecstasy, illicit drug 
use was largely restricted to cannabis (1 person reported occasional use of ketamine). 
Although there were group differences in cannabis and cocaine use, few reached statistical 
significance. However, the groups had marked differences in their periods of abstinence from 
all 3 illicit drugs. The non-ecstasy users had abstained significantly longer than current users 
from cannabis and previous ecstasy users had abstained significantly longer than current 
users from both cocaine and obviously from ecstasy.  
<<Insert Table 2 About Here>> 
Table 3 shows the outcomes (means and s.d.) for the BRIEF-A subscales for each of 
the three groups. With the exceptions of Shift and Emotional Control, the BRIEF subscales 
showed the current ecstasy/polydrug users performing worse (as indicated by a higher score) 
than the previous users and non-users. The better (lower) scores in the previous users and 
non-users were similar to one another. Multivariate analysis of variance, with the BRIEF-A 
subscale scores as dependent variables, and with drug use between participants and current 
cigarette and alcohol consumption as covariates, revealed a statistically significant 
multivariate group effect, Λ = .697, F(18,186) = 2.04, P <0.01, partial η2= .165. With the 2 
exceptions of Shift and Emotional Control, subsequent univariate analyses, reported in Table 
3, revealed that the group effect was statistically significant for each of the individual BRIEF-
A subscales.  
<<Insert Table 3 About Here>> 
We had predicted that both current and previous ecstasy/polydrug users would score 
significantly worse than non-users on measures of executive function. For current users, 7 of 
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the 9 pairwise comparisons (based on the least significant difference test) confirmed our 
prediction. However, our prediction did not prove true for previous users. In fact, the 
previous users and non-users did not differ significantly on any of the comparisons. It is also 
noteworthy that the previous users scored significantly better than the current users on 7 of 
the 9 BRIEF-A subscales. These pairwise comparisons remained significant after Bonferroni 
correction at the adjusted alpha level of .016 (≈ .05/3). 
As for the covariates, daily consumption of cigarettes was associated with a 
statistically significant multivariate effect, Λ = .758, F(9,93) = 3.30, P <0.01, partial η2= .242. 
Furthermore, all 9 of the univariate analyses produced statistically significant cigarette 
covariate effects: for Inhibit and Self-Monitor, P <0.001; for Emotional Control, Working 
Memory, and Plan/Organize, P <0.01; and for Shift, Initiate, and Task Monitor, P <0.05. 
Neither the multivariate nor the univariate alcohol-related covariate effects were statistically 
significant, P >0.05 in all cases. 
Because previous ecstasy users scored as unimpaired on the BRIEF-A, impaired 
executive function seems to be related to some aspect of current drug use. In addition to 
ecstasy, many current users were regularly consuming cocaine and cannabis. It is possible 
that any of these 3 drugs was responsible for the users’ impairment.  Nicotine or alcohol 
might also have contributed. 
To examine these possibilities, we conducted 9 multiple regression analyses with the 
BRIEF-A subscales as dependent variables. In each analysis, the independent variables were 
the current frequency of ecstasy, cannabis, and cocaine use; the number of units of alcohol 
consumed per week; and the number of cigarettes smoked per day. The results of these 
analyses are shown in Table 4. For each regression, the table contains the standardized beta 
weight, simple correlation, and semipartial correlation for each predictor. For the simple 
correlations, the current frequencies of ecstasy, cocaine, and cannabis use correlated 
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significantly with a number of the BRIEF-A subscales. For example, frequency of ecstasy 
was significantly correlated with the Inhibit, Self-Monitor, Initiate, Plan/Organize and Task 
Monitor subscales. Frequency of cocaine was significantly correlated with the Inhibit, Self-
Monitor, Initiate and Plan/Organize subscales and frequency of cannabis was significantly 
correlated with the Initiate subscale.  Frequency of ecstasy use was also significantly 
correlated with the higher-order Behavioral Regulation and Metacognition Indices as well as 
the Global Executive Composite score while frequency of cocaine use was significantly 
correlated with the Metacognition Index. In the regression analyses, the frequency of ecstasy 
use was statistically significant in the models for the Inhibit, Self-Monitor, and Task Monitor 
BRIEF-A subscales and for the higher-order Behavioral Regulation and Global Executive 
Composite BRIEF-A scales. The current frequencies of cocaine and cannabis use were not 
statistically significant as predictors in any of the regression equations.  
<<Insert Table 4 About Here>> 
What we had not predicted was the association between daily cigarette smoking and 
impaired executive function. This predictor, daily cigarette smoking, was statistically 
significant in 8 of the 9 the regressions for the BRIEF-A subscales. Smoking was also a 
significant predictor in the regression equations for the higher-order Behavioral Regulation, 
Metacognition, and Global Executive Composite BRIEF-A scales. Of note, for 6 of the 
BRIEF-A subscales, the cigarettes per day predictor was associated with the largest 
semipartial correlation coefficient, indicating that it accounted for the largest proportion of 
unique variance in the dependent variables For the remaining predictor, units of alcohol per 
week, a number of the simple correlations with the BRIEF-A measures were statistically 
significant. For instance, units of alcohol per week was significantly correlated with the 
Inhibit, Self-Monitor, Initiate, Plan/organize, Task Monitor and organization of materials 
subscales of the BRIEF-A as well as with the high-order Metacognition Index and Global 
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Executive Composite scales. However, weekly alcohol consumption was statistically 
significant in only 1 of the regression equations, that for the Plan/Organize BRIEF-A 
subscale. 
Although the number of cigarettes per day was clearly important as a predictor, the 
current ecstasy/polydrug users were impaired relative to the other groups even after we 
controlled for nicotine consumption in our analysis. However, Table 2 makes it clear that the 
previous ecstasy users not only had ceased using ecstasy but also had not consumed cocaine 
or cannabis for a long time. Indeed, the group difference for “weeks since last use” for these 
2 drugs was statistically significant. Similarly, the current ecstasy/polydrug users had a 
shorter period of abstinence for cannabis than did the other 2 groups; again, the overall group 
difference was statistically significant. It is possible, therefore, that the group differences 
observed in the current users’ executive functioning might be a result of the effects of 
cannabis or cocaine rather than ecstasy.  
To examine this possibility, we correlated the period of abstinence for the 3 major 
illicit drugs with the BRIEF-A subscales and the higher- order BRIEF-A scales. As shown in 
Table 5, only the period of abstinence from ecstasy correlated significantly with the executive 
function measures. Table 5 also reveals that, with just 1 exception, ecstasy, cocaine, and 
cannabis consumption during the previous 10 days was unrelated to the BRIEF-A outcomes. 
Thus, the current users’ findings for executive dysfunction do not reflect a short-term post-
intoxication effect. 
<<Insert Table 5 About Here>> 
The current users’ BRIEF-A scores could reflect some self-perceived general 
cognitive deficit,  perhaps in everyday memory processes, rather than a specific executive 
function deficit. This would potentially compromise the validity of the BRIEF-A and 
therefore it would be desirable to attempt to disconfirm this possibility. In our previous 
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studies,
32,33
 the same participants completed self-report measures of their real world memory 
functioning—the EMQ, PRMQ, and CFQ—and their partners or roommates completed the 
CFQ for Others to give  an external assessment. Although all 4 of these questionnaires tap 
processes that reflect prefrontal and medial temporal functions, the CFQ and CFQ for Others 
relate primarily to the efficacy of executive processes,
35
 the retrospective memory subscale of 
the PRMQ assesses the efficacy of recall in everyday contexts,
36
 and the EMQ contains 
questions that reflect both executive and medial temporal processes.
37
 Though the BRIEF-A 
subscales might be expected to correlate with all 4 of these measures, the correlation with the 
CFQ should be particularly robust given that both the BRIEF-A and the CFQ primarily 
reflect behaviors associated with executive processes.  
Thus if the BRIEF-A does primarily relate to executive processes then when the 
variance associated with more basic memory processes (as reflected in the EMQ and the 
PRMQ)  is removed then the partial correlations between the BRIEF-A and the CFQ should 
remain statistically significant since both these measures predominantly reflect executive 
processes. However when the variance associated with executive processes (as reflected in 
the CFQ) is removed the partial correlations between the BRIEF-A and the more basic 
memory measures, should no longer be statistically significant since any residual variance 
associated with executive processes in the EMQ and the PRMQ should have been removed. 
Table 6 shows correlations and partial correlations between the BRIEF-A measures and the 
other self-report measures of real-world memory. With the exception of the Shift and 
Emotional Control, all other 7 subscales of the BRIEF-A and the higher-order Behavioral and 
Metacognition Indices and Global Executive Composite scales were correlated with all of the 
other real-world memory measures. Controlled for individual differences in simple recall and 
memory functions as reflected in the EMQ and PRMQ, most of the correlations between the 
BRIEF-A and the CFQ remained statistically significant, reflecting the fact that both 
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measures concern executive functions. Partial correlations controlling for the CFQ would 
essentially remove the executive element from the other measures. When we controlled for 
the CFQ, the BRIEF-A no longer correlated significantly with the EMQ and the retrospective 
memory subscale of the PRMQ (Table 6, columns 5 and 7). It seems possible, therefore, that 
all 5 scales reflect, at least to some degree, self-perceptions of executive function or perhaps 
some general conception of cognitive capacity. However, it appears that the BRIEF-A, CFQ, 
and CFQ for Others relate primarily to executive functions, and the EMQ and the 
retrospective memory subscale of the PRMQ primarily reflect nonexecutive processes such 
as recall and learning. 
<<Insert Table 6 About Here>> 
The first column of Table 6 contains the correlations between the CFQ for Others and 
the BRIEF-A. Interestingly, all but 2 of the BRIEF-A subscales correlated significantly with 
the CFQ for Others, implying that the participants’ own assessment of their executive 
functions has at least some overlap with the assessment of their significant other.  
 
DISCUSSION 
Current ecstasy/polydrug users performed significantly worse than previous users and 
non-users on 7 of 9 BRIEF-A subscales, the exceptions being Emotional Control and Shift. 
The impairment was restricted to current ecstasy users; previous users showed no sign of 
executive dysfunction, performing similarly to nonusers. The current frequency of ecstasy 
use was significantly related to the executive function measure, with increasing frequency of 
use associated with worse BRIEF-A scores. Regression analyses revealed that the current 
frequency of ecstasy use accounted for statistically significant unique variance on 3 of the 
BRIEF-A subscales as well as the BRIEF-A higher-order Behavioral Regulation Index and 
the Global Executive Composite score.  
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Neither cannabis nor cocaine was associated with statistically significant unique 
variance on any of the BRIEF-A measures. The extent of executive dysfunction among the 
ecstasy users diminished with longer abstinence from the drug. However, executive function 
was unrelated to use of the 3 major illicit drugs—ecstasy, cannabis, and cocaine—within the 
previous 10 days. Thus, the perceived deficits were not restricted to participants with recent 
exposure to the drugs. 
In terms of the effect sizes from the  analyses of variance, the ecstasy-related 
difference was greatest for the BRIEF-A Inhibit subscale, for which we found an effect size 
of 21% (partial η2=.208). The effect sizes for the Self-Monitor, Task Monitor, and Initiate 
subscales ranged between 12.5% and 14.2%. For the remaining subscales, effect sizes were 
below 10%. The emergence of an ecstasy-related effect on the Inhibit subscale seems at first 
to be at odds with laboratory studies
 
(eg, Montgomery et al
23
) whose tests of inhibitory 
function failed to reveal ecstasy-related deficits. However, the BRIEF-A Inhibit scale covers 
aspects of impulsivity such as the propensity for fidgeting, restlessness, impatience, and 
distractibility. By contrast, laboratory tests focus on the ability to inhibit previously learned 
prepotent responses, as in the Stroop paradigm or random generation.
38
 
The BRIEF-A Task Monitor and Initiate subscales are associated with the ability to 
formulate and maintain goal-directed behavior—more specifically, the ability to initiate 
appropriate action sequences and to develop subgoals, monitor progress, and focus attention 
in a task-centered manner. Laboratory studies have shown that ecstasy users have problems 
updating the contents of their working memory (see Murphy et al
7
 for a review), failing to 
delete information that is no longer relevant, and being unable to incorporate new information 
effectively. They also seem to be less successful in accessing the contents of their semantic 
memory. Our study suggests that in the real world these problems may manifest themselves 
as an inability to maintain goal-directed behavior, and a tendency for impulsivity.  
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One of the laboratory tasks involving goal-directed behavior is the Tower of London 
Test. When ecstasy users have taken this test, the results have been mixed: Morgan
39
 failed to 
find any evidence of ecstasy-related impairment, but Fox et al
40
 found that ecstasy users took 
significantly longer to plan their initial moves on the task. Our results suggest that in the real 
world, where people face many distractions and interruptions, current ecstasy users might 
have impairments in the initiation and maintenance of goal-directed behavior. 
The existing evidence on impulsivity is also somewhat inconsistent, with some studies 
finding that ecstasy users perceive themselves to be more impulsive then nonusers on self-
report measures but do not exhibit this tendency in laboratory tests (eg, Clark, Roiser, 
Robbins, et al
41
), and other studies observing the opposite tendencies (eg, Schilt, Goudriaan, 
Koeter, et al
42
). Moeller, Dougherty, Steinberg, et al
43
 found that heavy ecstasy users 
exhibited impulsivity on both self-report and laboratory measures. Likewise, elevated 
impulsivity was evident among heavy ecstasy users in the Quednow, Kühn, Hoppe, et al
44
 
laboratory study. Morgan et al
39,45
 also found ecstasy users to have high levels of impulsivity 
on laboratory measures compared to nonusers. Our results suggest that ecstasy/polydrug users 
report problematic behaviors in real-world contexts stemming from their heightened 
impulsivity, but that this tendency diminishes as they abstain for longer periods. 
The BRIEF-A Self-Monitor subscale, on which our current ecstasy users also 
exhibited impairment, concerns the ability to understand the feelings of others and to 
anticipate the consequences of one’s actions. These types of behavior are believed to be 
supported by the orbitofrontal cortex. Indeed, Mah, Arnold, and Grafman
46
 found that social 
and interpersonal perception was impaired in people with orbitofrontal lesions. Similarly, 
Beer, John, Scabini, et al
47
 found that patients with orbitofrontal lesions exhibited 
inappropriate social behavior and that their actions were associated with impaired self-
monitoring ability. Neuroimaging studies of cocaine-dependent individuals have shown 
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decreased gray-matter volume in various cortical structures, including the orbitofrontal 
cortex, with the extent of the reduction related to the duration of cocaine dependence.
48
 
In our study, outcomes on the BRIEF-A Self-Monitor subscale were largely unrelated 
to cocaine use. Although the frequency of cocaine use correlated significantly with self-
monitoring performance, the cocaine measure failed to reach statistical significance in the 
corresponding regression equation. Our results implicate current ecstasy use as being 
associated with impaired self-monitoring. Some neuroimaging research links ecstasy use with 
reduced serotonin transporter densities in the orbitofrontal cortex; however, other brain 
regions have also exhibit similar or more severe reductions.
49
 
 Our ecstasy/polydrug users performed normally on the BRIEF-A Emotional Control 
subscale. At first sight, this outcome is at odds with the results of Reay et al,
50
 who found that 
ecstasy users were impaired on a measure of emotional intelligence. However, the BRIEF-A 
Emotional Control subscale covers primarily the personal expression of emotions, eg, the 
ability to control one’s temper. Emotional intelligence is a far broader construct that is more 
concerned with reading emotions in other people and acting appropriately. Interestingly, 
these aspects of emotional competence form part of the BRIEF-A Self-Monitor subscale, 
which, as noted earlier, addresses the ability to understand the feelings of others and to 
anticipate the consequences of one’s actions. As our ecstasy users were impaired on this 
subscale, our results are broadly consistent with those of Reay et al. 
An unanticipated finding of our study was the association of daily cigarette smoking 
with executive dysfunction. There is evidence that neural processing is adversely affected in 
abstinent smokers. For example, Xu, Mendrek, Cohen, et al
51
 found that, when performing an 
n-back task, left dorsolateral prefrontal cortex activity was higher in smokers who had 
abstained for a minimum of 14 hours compared to those who had smoked recently, even in 
conditions with low task load, and did not increase with higher loads. By contrast, activity 
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was lower in participants who had smoked recently, and increased with task load. The authors 
interpreted their results as indicating less efficient neural processing during short-term 
abstinence from nicotine. In a subsequent fMRI study by the same authors, smoking a 
cigarette after a period of abstinence (13 hours) increased neural processing efficiency, 
although smoking a cigarette in a satiated condition did not have this effect.
52
  
Temporary cessation from smoking thus appears to compromise neural function, 
presumably as a consequence of nicotine withdrawal. Consistent with this finding, abstinent 
smokers taking nicotine lozenges performed better than those taking placebo on tasks 
measuring executive functions, working memory, and attention.
53
  
It is also possible that regular smoking adversely affects executive function whether 
or not the individual is abstinent. For example, Jacobsen et al
54
 compared adolescent daily 
smokers with adolescent nonsmokers on tests of verbal memory and learning, verbal working 
memory, and attention. The investigators controlled for group differences in cannabis and 
alcohol use, baseline affect, intelligence, reading skill, age, sex, and parental education. The 
smokers were impaired on tests of working memory whether or not they had smoked 
recently, and the impairment was worse in those who had started smoking at an earlier age. 
During abstinence deficits in working memory were exacerbated and deficits in verbal 
memory also became apparent. 
In a later fMRI study by Jacobsen and colleagues,
55
 abstinent adolescent smokers -
performing a high-load executive function task had greater activation than non-smokers in 
specific areas known to support verbal working memory, such as the left ventrolateral 
prefrontal cortex and the left inferior parietal lobe. As task demands increased, the abstinent 
smokers did not display the  non-smokers’ increase in functional connectivity across the 
neural circuits supporting working memory processes. The authors attributed their findings to 
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the heightened neurotoxic potential of nicotine when tobacco is consumed earlier in 
adolescent development. 
It is unclear whether the adverse effects of smoking persist long-term. In a middle-
aged sample, women (but not men) diagnosed with a history of tobacco dependence 
performed worse than those without such a diagnosis on measures of processing speed, 
visuospatial processing, and executive functioning.
56
 In a sample with an average age older 
than 67, most aspects of cognitive functioning were unaffected by a history of smoking, but 
heavy smokers performed worse than light and moderate smokers on the Wisconsin Card 
Sorting Test .
57
 By contrast, Schinka, Vanderploeg, Rogish, et al
58
 studied people aged 60 to 
84 and failed to find any effects of lifelong smoking history on executive and other cognitive 
functions. However, in a sample of men with and without a history of alcoholism, Glass, Buu, 
Adams, et al
59
 found that estimates of lifetime smoking were negatively associated with 
executive functioning, particularly on tasks with a processing speed component.  
 Smoking-related impairment in self-reported executive functioning is a cause for 
concern, at least for current smokers during periods of abstinence. Now that many places ban 
indoor smoking, it is likely that learning and memory will be adversely affected. This is a 
particular concern for people in higher education, like our student study participants, and 
more generally for people engaged in cognitively demanding activities. 
Our study had some limitations. As with most studies in this field, ours had no 
objective measure of drug use, such as urinalysis or hair analysis; such a measure would have 
been desirable to confirm participants’ self-reports. Another consideration is that the self-
reported apparent ecstasy/polydrug-related deficits may not have been a direct consequence 
of illicit drug use, but rather of differences between users and nonusers predating their illicit 
drug use. Although pre-existing differences between study groups are clearly a possibility, the 
absence of deficits among the previous ecstasy users might cast some doubt on this 
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explanation. It is also possible that the effects that we observed in our current users were 
related to lifestyle differences or to the physiological effects of illicit drug use, such as 
impaired sleep quality,
60
 rather than having a direct pharmacological basis. 
Although the psychometric integrity of the BRIEF-A has been documented, our 
results further confirm its validity. Our participants completed not only the BRIEF-A but also 
the CFQ, which is believed to reflect executive processes, and the PRMQ and EMQ, which 
reflect more basic memory processes and other more general aspects of everyday cognition. 
After controlling for other real-world memory measures, we found that the BRIEF-A shared 
unique variance with the CFQ . Given that the CFQ is believed to reflect executive processes, 
our finding suggests that the BRIEF-A does indeed selectively capture this aspect of 
cognitive functioning. Furthermore, when the executive component of the other real-world 
memory measures, the PRMQ and EMQ, was attenuated by our controlling for individual 
differences on the CFQ, the correlations between these measures and the BRIEF-A scores 
were no longer statistically significant. Thus, the BRIEF-A seems to reflect executive 
processes rather than the more basic memory functions tapped by the PRMQ and EMQ. It is 
also noteworthy that our participants’ BRIEF-A scores correlated with the CFQ for Others 
ratings, implying that the participants’ own assessment of their executive functions has some 
degree of overlap with the assessment of their significant other.  
Given that the BRIEF-A has been shown to share variance with these other self-report 
measures, we should point out that ecstasy/polydrug-related deficits have also been observed 
on the CFQ, EMQ, and PRMQ. For example, Montgomery and Fisk
61
 found that 
ecstasy/polydrug users reported more everyday memory problems than did non-users on the 
EMQ, and more cognitive failures on the CFQ. More recently, Hadjiefthyvoulou et al
32
 found 
that ecstasy/polydrug users were impaired on the EMQ and that the effect remained 
significant after controlling for cannabis, alcohol, and nicotine use. In the same study, 
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although the overall group effect was not significant for the CFQ, cognitive failures were 
positively associated with lifetime ecstasy consumption and current frequency of use. Lastly, 
although the PRMQ has received less attention in the substance abuse literature than other 
measures, a recent study
33
 found that ecstasy/polydrug users were also impaired on this 
measure. The fact that illicit drug users are impaired on the BRIEF-A and these other 
measures of real-world memory is consistent with the proposition that, to some degree, all the 
measures reflect the operation of executive resources. 
To conclude, we intended to determine the impact of ecstasy/polydrug use on 
executive function using the self-report BRIEF-A. Our current ecstasy/polydrug users 
performed significantly worse than long-term abstinent previous users and non-users on 7 of 
9 BRIEF-A subscales, the exceptions being the ability to shift mental set and to regulate 
emotions. The current frequency of ecstasy use accounted for significant unique variance on 
the Inhibit, Self-Monitor, and Task Monitor subscales and on the Behavioral Regulation and 
overall composite higher order scales. An unanticipated finding was the association of daily 
cigarette smoking with executive dysfunction. 
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TABLE 1.  Demographic Variables for Current and Previous Ecstasy/Polydrug Users and Non-users  
 
 
 
Current 
Ecstasy/Polydrug 
Users 
Previous 
Ecstasy/Polydrug 
Users 
Non-users of 
Ecstasy  
P
a
 
 Mean SD N Mean SD n Mean SD n  
           
Age (y) 21.05 2.00 42 22.33 4.23 18 21.14 2.90 50 NS 
Raven’s Progressive 
   Matrices (maximum 60) 
44.34 8.66 42 39.33 7.62 18 43.34 7.77 50 NS 
Education (y) 15.12 3.35 41 14.56 3.63 18 14.92 2.63 50 NS 
Cigarettes (per day) 7.44 4.26 16 12.40 11.07 10 7.38 5.99 13 NS  
Alcohol (units per week) 15.76 11.10 42 9.82 6.26 17 9.28 9.76 47 0.007 
           
 
a 
For one-way analysis of variance. 
SD indicates standard deviation; NS, not significant. 
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TABLE 2. Background Drug Use for Current and Previous Ecstasy/Polydrug Users  and Non-users  
 
 
Current Ecstasy/Polydrug Users Previous Ecstasy/Polydrug Users Non-users of Ecstasy  P
a
 
 Median Mean SD n Median Mean SD n Median Mean SD n  
              
Total lifetime use              
Ecstasy (tablets) 221 750.29 1293.51 42 149 395.44 885.49 18 - - - 0 NS 
Cannabis (joints) 900 3358.11 4883.61 37 572 2709.88 5205.16 16 192 1578.47 2928.16 17 NS 
Cocaine (lines) 436 1131.47 1596.75 30 108 746.78 929.41 9 - - - 0 NS 
Current frequency of 
use (times per week) 
             
Ecstasy 0.25 0.35 0.40 42 0 0 0 18 - - - 0 -  
Cannabis 0.50 1.65 2.35 37 0.05 1.03 2.12 16 0.04 1.52 2.55 17 NS 
Cocaine 0.25 0.38 0.44 30 0.02 0.15 0.35 8 - - - 0 NS 
Weeks since last use              
Ecstasy 3 5.71 6.24 42 52 105.33 92.69 18 - - - 0 <0.00
1 
Cannabis 1 15.27 40.70 38 24 34.19 42.52 15 12 72.44 103.77 17 0.010 
Cocaine 2 9.63 15.21 35 16 30.09 31.65 10 - - - 0 0.006 
Weeks since first use              
Ecstasy 156 182.31 121.46 42 223 252.94 145.27 18 - - - 0 NS 
Cannabis 260 304.45 142.53 38 296 382.13 272.67 15 308 323.53 219.23 17 NS 
Cocaine 122 161.83 113.91 35 260 255.64 134.62 11 - - - 0 0.027 
              
 
a
For one-way analysis of variance, comparing current and previous ecstasy users for cocaine and ecstasy, and all 3 groups for cannabis. 
NS indicates not significant.
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TABLE 3. Outcomes on the Self-Report BRIEF-A for Current and Previous Ecstasy/Polydrug Users and Non-users 
 
 
a
For analysis of covariance with drug use between participants and units of alcohol per week and cigarettes per day as covariates. One previous 
user and 3 non-users did not provide values for the covariates. 
 
b
For least significant differences without adjustment for multiple comparisons. 
BRIEF-A indicates Behavior Rating Inventory of Executive Function-Adult Version; SD, standard deviation; NS, not significant.
BRIEF-A Subscale Current 
Ecstasy/Polydrug 
Users (n = 42) 
Previous 
Ecstasy/Polydrug 
Users (n = 18) 
Non-users of 
Ecstasy 
(n = 50) 
Overall Effect:
a
 
F(2,101)  
Pairwise Comparisons: P
b
 
 Mean SD Mean SD Mean SD P Partial η2 Current vs 
Non-user 
Current vs 
Previous 
Non-user 
vs Previous 
             
Inhibit 16.29 2.22 13.94 3.61 13.88 2.81 <0.001 .208 <0.001 <0.001 NS 
Shift 9.79 2.40 10.17 2.96 9.76 2.26 NS     
Emotional Control 17.02 4.71 17.11 3.77 17.52 4.56 NS     
Self-Monitor 10.86 2.55 9.50 2.83 9.22 2.05 0.001 .134 0.003 0.001 NS 
Initiate 15.60 2.95 13.67 3.45 13.42 2.52 <0.001 .142 0.001 0.001 NS 
Working Memory 15.05 3.04 14.17 4.09 13.52 2.81 0.010 .088 0.007 0.015 NS 
Plan/Organize 18.48 4.33 16.22 4.33 15.88 3.19 0.007 .093 0.007 0.010 NS 
Task Monitor 11.76 2.40 10.44 2.31 10.20 1.80 0.001 .125 0.002 0.002 NS 
Organization of 
    Materials 
15.74 4.03 13.17 3.64 13.08 3.69 0.007 .093 0.013 0.005 NS 
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TABLE 4. Regression Analyses with the BRIEF-A Subscales as Dependent Variables and Drug Use Patterns as Predictors 
 
 
*P <0.05; **P <0.01; ***P <0.001. 
BRIEF-A indicates Behavior Rating Inventory of Executive Function-Adult Version.
BRIEF-A Subscale Current Frequency of Use for: Cigarettes per Day Alcohol (Units per Week) R
2
 
 Ecstasy Cannabis Cocaine    
  Β r: Simple/ 
Semi-partial  
 Β r: Simple/ 
Semi-partial  
 β r: Simple/ 
Semi-partial  
 β r: Simple/ 
Semi-partial  
 β r: Simple/ 
Semi-partial  
  
Inhibit 
 
 
.322 
.337*** 
.271** 
 
-.115 
 .110 
-.103 
 
 .040 
 .266** 
 .035 
 
.356 
.367*** 
.340*** 
 
 .183 
 .235* 
 .177 
 
.280*** 
Shift 
 
 
.107 
.027 
.090 
 
-.083 
-.012 
-.074 
 
-.121 
-.047 
-.105 
 
.291 
.248** 
.278** 
 
-.111 
-.112 
-.107 
 
.094 
Emotional Control 
 
 
.181 
.080 
.152 
 
-.062 
 .036 
-.055 
 
-.192 
-.081 
-.167 
 
.302 
.255** 
.289** 
 
-.095 
-.094 
-.092 
 
.114 
Self-Monitor 
 
 
.292 
.319*** 
.246** 
 
-.054 
 .156 
-.048 
 
 .025 
 .237* 
 .022 
 
.347 
.366*** 
.332*** 
 
 .170 
 .227* 
 .164 
 
.257*** 
Initiate 
 
 
.209 
.277** 
.176 
 
 .070 
 .198* 
 .062 
 
 .059 
 .195* 
 .051 
 
.150 
.193* 
.143 
 
 .109 
 .171* 
 .105 
 
.130* 
Working Memory 
 
 
.094 
.143 
.079 
 
 .067 
 .162 
 .060 
 
 .026 
 .119 
 .022 
 
.253 
.279** 
.242* 
 
 .034 
 .084 
 .033 
 
.101 
Plan/Organize 
 
 
.207 
.257** 
.174 
 
-.039 
 .133 
-.035 
 
 .060 
 .228* 
 .052 
 
.234 
.264** 
.223* 
 
 .240 
 .286** 
 .232* 
 
.192** 
Task Monitor 
 
 
.271 
.249** 
.228* 
 
-.094 
 .077 
-.084 
 
-.046 
 .132 
-.040 
 
.222 
.218* 
.212* 
 
 .161 
 .185* 
 .155 
 
.133* 
Organization of 
    Materials 
 
.088 
.103 
.074 
 
-.034 
 .094 
-.031 
 
-.020 
 .098 
-.018 
 
.276 
.284** 
.264** 
 
 .193 
 .216* 
 .187 
 
.124* 
            
Behavior Regulation 
    Index 
 
.289 
.236* 
.243* 
 
-.100 
 .090 
-.089 
 
-.097 
 .100 
-.085 
 
.414 
.390*** 
.396*** 
 
.034 
.065 
.033 
 
.213*** 
Metacognition Index 
 
 
.194 
.235* 
.163 
 
-.007 
 .156 
-.006 
 
.022 
 .183* 
 .019 
 
.271 
.297** 
.259** 
 
.182 
.230* 
.176 
 
.171** 
            
Global Executive 
Composite 
 
 
.254 
.257** 
.214* 
 
-.048 
 .142 
-.043 
 
-.028 
 .164 
-.024 
 
.360 
.366*** 
.343*** 
 
.134 
.180* 
.130 
 
.210*** 
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TABLE 5. Correlations Between BRIEF-A Subscales  and Abstinence Duration and Recent Use of Ecstasy, Cannabis, and Cocaine  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*P <0.05; **P <0.01; ***P <0.001. 
 
BRIEF-A indicates Behavior Rating Inventory of Executive Function-Adult Version. 
 
BRIEF-A Subscale 
 
Weeks Since Last Use  Use in the Past 10 Days 
 Ecstasy 
(n=60) 
Cannabis 
(n=70) 
Cocaine 
(n=45) 
 Ecstasy 
(n=60) 
Cannabis 
(n=72) 
Cocaine 
(n=46) 
Inhibit -.527*** -.159 -.247  .162 .076 -.007 
Shift -.216  .092  .003  .064 .049 -.063 
Emotional Control -.104  .132 -.066  .129     .303** -.004 
Self-Monitor -.314* -.044 -.228  .162 .113 .035 
Initiate -.394** -.187 -.208  .113 .067 -.002 
Working Memory -.332** -.015 -.184  .004 .080 -.051 
Plan/Organize -.325* -.166 -.252  .100 .192 -.050 
Task Monitor -.377** -.144 -.173     -.013 .154 -.141 
Organization of 
    Materials 
-.302* -.184 -.144  .081 .146 -.103 
        
Behavior Regulation 
    Index 
-.329*  .025 -.152  .159 .192 -.011 
Metacognition Index -.403** -.170 -.235  .075 .157 -.079 
        
Global Executive 
Composite 
-.395** -.093 -.215  .116 .182 -.055 
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TABLE 6. Correlations Between BRIEF-A Subscales and Other Measures of RealWorld Memory
a
 
 
a
n = 97 unless otherwise noted 
 
*P <0.05; **P <0.01; ***P <0.001. 
 
BRIEF-A indicates Behavior Rating Inventory of Executive Function-Adult Version; CFQ, Cognitive Failures Questionnaire; PRMQ, Prospective and Retrospective Memory 
Questionnaire; RM, Real-World Memory. 
BRIEF-A Subscale 
 
CFQ for 
Others 
(n=44) 
CFQ CFQ Controlling for Everyday 
Memory and Crawford’s 
PRMQ RM Subscale 
Everyday 
Memory  
Everyday Memory 
Controlling for 
CFQ 
Crawford’s 
PRMQ RM 
Subscale 
Crawford’s PRMQ 
RM Subscale 
Controlling for CFQ 
Inhibit .313* .487*** .386*** .201* -.121 .342*** -.024 
Shift .282 .422*** .270** .254* .008 .337*** .046 
Emotional Control .192 .316** .197 .119 -.088 .277** .071 
Self-Monitor .361* .397*** .176 .274** .055 .390*** .158 
Initiate .453** .604*** .340*** .398*** .066 .562***   .221* 
Working Memory .515*** .638*** .360*** .475*** .160 .585***   .224* 
Plan/Organize .546*** .646*** .452*** .401*** .035 .515*** .081 
Task Monitor .500*** .599*** .346*** .374*** .034 .551***   .207* 
Organization of 
    Materials 
.532*** .524*** .437*** .231* -.111 .339*** -.076 
        
Behavior 
   Regulation Index 
.351* .514*** .342*** .255* -.068 .427*** .087 
Metacognition 
    Index 
.589*** .710*** .501*** .436*** .033 .589*** .146 
        
Global Executive 
Composite 
 
.542*** .693*** .491*** .399*** -.014 .575*** .139 
